<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CETUXIMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CETUXIMAB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated</span>,
                <span class="indication">Treatment of locally advanced squamous cell cancer of the head and neck (in combination with radiotherapy)</span>,
                <span class="indication">Treatment of recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (initiated by a specialist)</strong><br/>
                (consult product literature or local protocols).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk&#8212;no information available.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><i>RAS</i> mutated colorectal tumours (or if <i>RAS</i> tumour status unknown)</li>
            <li>combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown <i>RAS</i> status</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Acne, aseptic meningitis, blepharitis, bronchospasm, chills, conjunctivitis, desquamation, diarrhoea, dizziness, dry skin, dyspnoea, fever, headache, hypertension, hypertrichosis, hypocalcaemia, hypomagnesaemia, hypotension, infusion-related reactions, keratitis, nail disorders, nausea, pruritus, rash, severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset), shock, skin reactions, urticaria, vomiting,
              </p>
              <p>
                <strong>veryRare:</strong> Stevens-Johnson syndrome, toxic epidermal necrolysis,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Resuscitation facilities should be available.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA145</h3>
              <p outputclass="title">Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008)</p> <p>Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.</p><xref format="html" href="http://www.nice.org.uk/TA145">www.nice.org.uk/TA145</xref>
                <a href="http://www.nice.org.uk/TA145" target="_blank">www.nice.org.uk/TA145</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA172</h3>
              <p outputclass="title">Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009)</p> <p>Cetuximab in combination with platinum-based chemotherapy is <b>not</b> recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.</p><xref format="html" href="http://www.nice.org.uk/TA172">www.nice.org.uk/TA172</xref>
                <a href="http://www.nice.org.uk/TA172" target="_blank">www.nice.org.uk/TA172</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA176</h3>
              <p outputclass="title">Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)</p> <p>Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:</p> <ul> <li>the primary tumour has been resected or is potentially operable;</li> <li>the metastatic disease is confined to the liver and is unresectable; and</li> <li>the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.</li> </ul> <p>In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.</p> <p>In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.</p> <p>Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.</p><xref format="html" href="http://www.nice.org.uk/TA176">www.nice.org.uk/TA176</xref>
                <a href="http://www.nice.org.uk/TA176" target="_blank">www.nice.org.uk/TA176</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA242</h3>
              <p outputclass="title">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p> <p>Cetuximab monotherapy or combination chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.</p><xref format="html" href="http://www.nice.org.uk/TA242">www.nice.org.uk/TA242</xref>
                <a href="http://www.nice.org.uk/TA242" target="_blank">www.nice.org.uk/TA242</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)</h3>
              <p>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p>
            </section>
            <section class="importantSafetyInformation">
              <p>Patients must receive an antihistamine and a corticosteroid at least one hour before infusion. Resuscitation facilities should be available and treatment should be initiated by a specialist.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiopulmonary disease
          </li>
          <li>
            cardiovascular disease
          </li>
          <li>
            history of keratitis
          </li>
          <li>
            pulmonary disease&#8212;discontinue if interstitial lung disease
          </li>
          <li>
            risk factors for keratitis
          </li>
          <li>
            severe dry eye
          </li>
          <li>
            ulcerative keratitis (including contact lens use)
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>







      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>Evidence of non-mutated (wild-type) <i>RAS</i> status (at exons 2, 3 and 4 of <i>KRAS</i> and <i>NRAS</i>) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CETUXIMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75856"><a href="../medicinalForm/PHP75856.html" data-target="#PHP75856" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
